



Borsika Rabin: Great presentations!! Thank you!!

Bethany Kwan: I love my surveys but it's just not pragmatic

Borsika Rabin: I appreciated Dr. Kilbourne talking about situations where randomization might not be best choice/feasible - would you say more about that? How we can justify this best in our proposals?

russglasgow: On Amy H's point about the 'funnel'..think it is important to consider this panel at all the various levels.... Community, health system, clinics, practioners, etc.

Bethany Kwan: For funding pragmatic research you might attend the getting funded in pragmatic research networking lunch today!

Bethany Kwan: Led by Dr. Russ Glasgow and Dr. Jodi Holtrop

russglasgow: Amy K's point about including midlevel managers is so critical IMHO... can be less of death if left out and they feel 'blindsided'

Borsika Rabin: I love this point about the limited capacity of efficacy research to inform effectiveness and eventual dissemination...

Bethany Kwan: How to win friends and influence people by Dale Carnegie - it's so great for so many reasons, including building partnerships and connections with communities and other researchers

Bethany Kwan: Several of this summers' D4D&S course students are here today!

Halden Scott: I was intrigued by Dr. Kilbourne's comments about not randomizing the order in which sites receive a step wedge intervention. I have been struggling with this question - when partnering with clinical teams on a complicated interdisciplinary intervention, it really helps them to be able to give them a time frame for intervention. Can you give some suggestions on how to justify this in a grant application or manuscript? Any examples that have discussed this nicely?

Bethany Kwan: Attend Mike Baiocchi's session on nonrandomized observational designs and natural experiments this afternoon for more on that

russglasgow: What about the role of costs in pragmatic research? Do you feel this should be routinely assessed and reported)? If so, using what approaches (just time, cost-utility, business case) and to whom?

DISCLAIMER: This is an unedited chat transcript of a Colorado Pragmatic Research in Health Conference (COPRH Con) held on August 11th-12th 2020 and is presented offered as a resource "as is." The content of this transcript is uncorrected and has not been proof read. Opinions and statements included in the transcript are solely those of the individual person(s), presenter(s) or participant(s) at the meeting, and are not necessarily adopted, endorsed or verified as accurate by ACCORDS or LearningTimes.



russglasgow: And on tissue of transparent reporting that Amy H mentioned...this is so important- she led important option for standard way to report this issue of representativeness at multiple levels...the 'Expanded CONSORT in Amer J Prev Medicine..I think 2018?

Bethany Kwan: We will have a 10 minute break at 10 after

Bethany Kwan: For the next session, go to the conference website and view 3 of the 20-minute recordings on frameworks and then join us for a panel discussion on frameworks led by Borsika Rabin

Amy Huebschmann: @jimcahill - check out the recent iterative RE-AIM paper by Russ Glasgow and colleagues about mid-stream pivots.

KATH Stevens: Thank you for a GREAT morning

DISCLAIMER: This is an unedited chat transcript of a Colorado Pragmatic Research in Health Conference (COPRH Con) held on August 11th-12th 2020 and is presented offered as a resource "as is." The content of this transcript is uncorrected and has not been proof read. Opinions and statements included in the transcript are solely those of the individual person(s), presenter(s) or participant(s) at the meeting, and are not necessarily adopted, endorsed or verified as accurate by ACCORDS or LearningTimes.